发明名称 Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
摘要 Disclosed is a method of predicting clinical responsiveness to glatiramer acetate therapy in a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis, the method comprising evaluating a biomarker selected from the group consisting of IL-17 concentration, TNF-alpha concentration, IL-2 concentration and IFN-gamma concentration, or a combination thereof, in the supernatant of PBMCs derived from the human subject is blood, thereby predicting clinical responsiveness to glatiramer acetate, wherein if the biomarker selected is IL-17 concentration then the human subject is identified as a glatiramer acetate responder if the IL-17 concentration is greater than or equal to 120 pg/ml.
申请公布号 NZ609938(A) 申请公布日期 2015.11.27
申请号 NZ20110609938 申请日期 2011.10.10
申请人 TEVA PHARMACEUTICAL INDUSTRIES LTD. 发明人 KASPER LLOYD H.;SMITH JACQUELINE Y.
分类号 C07K14/47;A61K38/00;A61K38/06;A61K38/07;A61P19/08;G01N33/68 主分类号 C07K14/47
代理机构 代理人
主权项
地址